The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
Read about the latest insights in skin cancer care with a new whitepaper on advanced basal cell carcinoma and advanced cutaneous squamous cell carcinoma. View the complimentary resource today!
Researchers aimed to compare the transcriptome of psoriatic arthritis (PsA) skin with healthy control skin by evaluating atypical chemokine receptor 2 (ACKR2) expression in PsA skin.
Researchers aimed to compare the transcriptome of psoriatic arthritis (PsA) skin with healthy control skin by evaluating atypical chemokine receptor 2 (ACKR2) expression in PsA skin.
New research from the National Eczema Association reveals that eczema patients and caregivers want to be involved in decision-making for their treatments.
New research from the National Eczema Association reveals that eczema patients and caregivers want to be involved in decision-making for their treatments.
Drs Hao Feng and Eric Beltrami discussed the travel and time burdens surrounding psoriasis clinical sites following their study, “Differential Patient Travel Distance and Time to Psoriasis Clinical Trial Sites.”
Drs Hao Feng and Eric Beltrami discussed the travel and time burdens surrounding psoriasis clinical sites following their study, “Differential Patient Travel Distance and Time to Psoriasis Clinical Trial Sites.”
Following her recent study, Dr Abigail Cline discusses what further research is needed to evaluate dupilumab’s effectiveness and the occurrence of adverse effects.
Following her recent study, Dr Abigail Cline discusses what further research is needed to evaluate dupilumab’s effectiveness and the occurrence of adverse effects.
Explore how patients and providers can align on defining atopic dermatitis (AD) flares to improve communication, treatment decisions, and shared decision-making. Take this interactive quiz to test your knowledge and learn how patient-centered...
Explore how patients and providers can align on defining atopic dermatitis (AD) flares to improve communication, treatment decisions, and shared decision-making. Take this interactive quiz to test your knowledge and learn how patient-centered...
How well do you understand the patient perspective on atopic dermatitis flares? Take this quiz to explore key patient-described flare indicators, emotional and social impacts, and insights from NEA research.
How well do you understand the patient perspective on atopic dermatitis flares? Take this quiz to explore key patient-described flare indicators, emotional and social impacts, and insights from NEA research.
Test your knowledge of how patients with atopic dermatitis (AD) define and experience flares. This quiz highlights key indicators, patient-described attributes, and insights from the NEA’s research into AD flare triggers and symptoms.
Test your knowledge of how patients with atopic dermatitis (AD) define and experience flares. This quiz highlights key indicators, patient-described attributes, and insights from the NEA’s research into AD flare triggers and symptoms.
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
2. Which of the following is associated with this condition? 
1. This antinuclear antibody (ANA) is most characteristic of:
2. Which of the following is associated with this condition?
